Apolipoprotein A5 (APOA5) -1131T>C polymorphism has been associated with differences in plasma triglycerides levels in different populations, since the allele variation seems to have a significant effect on interindividual variation in plama triglycerides and lipoprotein levels. This study investigated the association between the APOA5 -1131T>C polymorphism and coronary artery disease (CAD) extent.Methods
The APOA5 genotypes were determined by RFLP-PCR method in blood sample of 32 subjects with normal angiographycally coronary arteries, 26 subjects presenting mild/moderate atheromatosis, 51 subjects presenting severe atheromatosis and 35 healthy subjects (controls). Plasma lipids, lipoproteins and apolipoproteins A-I and B were determinated enzimatically.Results
No significant differences were observed for lipid, lipoprotein and apolipoprotein profiles among groups. The detected genetic frequencies for APOA5 alleles were 0.81 for T allele and 0.19 for C allele. No significant differences were observed for the allelic and genotypic frequencies of APOA5 polymorphism among the groups. Allele C presence was not associated with lipid variables. There was a negative correlation between the presence of C allele and apolipoprotein A-I (r=-0.37, p= < 0.0001) and apolipoprotein B (r=-0.25, p=0.003).Conclusions
In this study we have observed no influence of the APOA5 -1131T>C polymorphism on individual markers of lipid plasma levels in CAD patients. The frequencies of APOA5 alleles for controls and patients were similar to those described for other population. The APOA5 genotypes were not associated with severity of CAD and did not provide further information in these subjects concerning to atheromatosis extent. However, because our observations are based on a small group of patients, additional studies are essential to elucidate the possible relationship between the APOA5 -1131T>C polymorphism and CAD severity.